Literature DB >> 19390055

Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis.

Li Zhu1, Timothy J Stalker, Karen P Fong, Hong Jiang, Anh Tran, Irene Crichton, Eric K Lee, Keith B Neeves, Sean F Maloney, Hitoshi Kikutani, Atsushi Kumanogoh, Ellen Pure, Scott L Diamond, Lawrence F Brass.   

Abstract

OBJECTIVE: In dyslipidemic states, platelets become hyperreactive, secreting molecules that promote atherosclerosis. We have shown that the semaphorin family member, sema4D (CD100), is expressed on the surface of platelets and proposed that its role includes promoting thrombus growth by binding to nearby platelets and endothelial cells, both of which express sema4D receptors. Here we tested the hypothesis that deleting sema4D will attenuate the adverse consequences of dyslipidemia on platelets and the vessel wall. METHODS AND
RESULTS: Platelet function and atherosclerotic lesion formation were measured in LDLR(-/-) and sema4D(-/-)LDLR(-/-) mice after 6 months on a high-fat diet. All of the mice developed the dyslipidemia expected on this diet in the absence of functional LDL receptors. However, when compared to LDLR(-/-) mice, sema4D(-/-) LDLR(-/-) mice had reduced lipid deposition in the descending aorta, a 6-fold decrease in the frequency of arterial occlusion and a reduction to near wild-type levels in the accumulation of platelets after injury. These differences were retained ex vivo, with a marked decrease in platelet accumulation on collagen under flow and in platelet aggregation.
CONCLUSIONS: These results show that loss of sema4D expression reduces the platelet hyperactivity otherwise found in dyslipidemia, and confers protection against the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390055      PMCID: PMC2877695          DOI: 10.1161/ATVBAHA.109.185405

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  Platelet P-selectin facilitates atherosclerotic lesion development.

Authors:  Peter C Burger; Denisa D Wagner
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

2.  Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.

Authors:  Gregor Theilmeier; Carine Michiels; Erik Spaepen; Ingrid Vreys; Désiré Collen; Jos Vermylen; Marc F Hoylaerts
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration.

Authors:  S Delaire; C Billard; R Tordjman; A Chédotal; A Elhabazi; A Bensussan; L Boumsell
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

4.  Localized reduction of atherosclerosis in von Willebrand factor-deficient mice.

Authors:  N Methia; P André; C V Denis; M Economopoulos; D D Wagner
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.

Authors:  A J Cayatte; Y Du; J Oliver-Krasinski; G Lavielle; T J Verbeuren; R A Cohen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

6.  Alpha2beta1 integrin and development of atherosclerosis in a mouse model: assessment of risk.

Authors:  David G Grenache; Trey Coleman; Clay F Semenkovich; Samuel A Santoro; Mary M Zutter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-09-25       Impact factor: 8.311

7.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse.

Authors:  Shahrokh Falati; Peter Gross; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

8.  Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice.

Authors:  Tillmann Cyrus; Syuan Sung; Lei Zhao; Colin D Funk; Syun Tang; Domenico Praticò
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

9.  Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice.

Authors:  Arnon Afek; Evgeny Kogan; Sofia Maysel-Auslender; Adi Mor; Ehud Regev; Ardon Rubinstein; Gad Keren; Jacob George
Journal:  Microvasc Res       Date:  2009-01-31       Impact factor: 3.514

10.  A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation.

Authors:  Steffen Massberg; Korbinian Brand; Sabine Grüner; Sharon Page; Elke Müller; Iris Müller; Wolfgang Bergmeier; Thomas Richter; Michael Lorenz; Ildiko Konrad; Bernhard Nieswandt; Meinrad Gawaz
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

View more
  26 in total

1.  Deciphering the human platelet sheddome.

Authors:  Karen P Fong; Colin Barry; Anh N Tran; Elizabeth A Traxler; Kenneth M Wannemacher; Hsin-Yao Tang; Kaye D Speicher; Ian A Blair; David W Speicher; Tilo Grosser; Lawrence F Brass
Journal:  Blood       Date:  2010-10-20       Impact factor: 22.113

2.  Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia.

Authors:  B Nagy; J Jin; B Ashby; M P Reilly; S P Kunapuli
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

3.  Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention.

Authors:  Amarylis Wanschel; Tara Seibert; Bernd Hewing; Bhama Ramkhelawon; Tathagat D Ray; Janine M van Gils; Katey J Rayner; Jonathan E Feig; Edward R O'Brien; Edward A Fisher; Kathryn J Moore
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-21       Impact factor: 8.311

Review 4.  Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2).

Authors:  Kathryn J Moore; Simon Koplev; Edward A Fisher; Ira Tabas; Johan L M Björkegren; Amanda C Doran; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2018-10-30       Impact factor: 24.094

Review 5.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

Review 6.  Biology and function of neuroimmune semaphorins 4A and 4D.

Authors:  EusebiusHenry Nkyimbeng-Takwi; Svetlana P Chapoval
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

Review 7.  The role of semaphorins and their receptors in platelets: Lessons learned from neuronal and immune synapses.

Authors:  Kenneth M Wannemacher; Le Wang; Li Zhu; Lawrence F Brass
Journal:  Platelets       Date:  2011-06-13       Impact factor: 3.862

Review 8.  Immunological functions of the neuropilins and plexins as receptors for semaphorins.

Authors:  Atsushi Kumanogoh; Hitoshi Kikutani
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

Review 9.  Semaphorins 4A and 4D in chronic inflammatory diseases.

Authors:  Svetlana P Chapoval; Zahava Vadasz; Andrei I Chapoval; Elias Toubi
Journal:  Inflamm Res       Date:  2016-08-23       Impact factor: 4.575

Review 10.  Mouse laser injury models: variations on a theme.

Authors:  Timothy J Stalker
Journal:  Platelets       Date:  2020-04-16       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.